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Abstract
Background Tacrolimus (TAC) is an immunosuppressive
macrolide that blocks T-cell activation by specifically
inhibiting calcineurin. TAC was approved in Japan for the
treatment of rheumatoid arthritis (RA) in 2005. However,
the safety and effectiveness of TAC adding on to biological
disease-modifying anti-rheumatic drugs (DMARDs) in the
real clinical setting may not be clear enough.
Objectives We report here the interim results of post
marketing surveillance (PMS) of TAC adding on to bio-
logical DMARDs in RA patients who failed to show an
adequate response to biological DMARDs.
Methods Patients who had an inadequate response to
biological DMARDs were enrolled. An inadequate
response to biological DMARDs was defined as that all of
the following conditions were met: a Simplified Disease
Activity Index (SDAI) score of[3.3 when TAC was
started; both the tender joint count and swollen joint count
were the same or increased compared with those at
4–8 weeks prior to TAC; and biological DMARDs were
used for at least 8 weeks prior to TAC. This study was
conducted in compliance with the ministerial ordinance on
‘‘Good Post-Marketing Study Practice’’ (GPSP).
Results The safety data collection and evaluation for 172
patients and effectiveness data collection and evaluation for
165 patients were reported. The mean age was 61.9 years.
Adverse drug reactions occurred in 18 patients. The mean
SDAI decreased from 20.1 at baseline to 11.7 at week 24.
Conclusions TAC is well tolerated and effective when
added on to biological DMARDs in RA patients who failed
to achieve an adequate response to biological DMARDs.
Key Points
It has been reported that biological disease-
modifying anti-rheumatic drugs (DMARDs) fail to
achieve adequate suppression of disease activity and
that the effectiveness of biological DMARDs is
reduced in some patients.
Tacrolimus (TAC) adding on to biological DMARDs
in patients who failed to achieve an adequate
response to biological DMARDs was well tolerated
and improved the clinical outcome.
This study suggests that TAC in combination with
biological DMARDs can be one of the options in
patients with rheumatoid arthritis who failed to show
an adequate response to biological DMARDs in the
real clinical setting.
1 Introduction
Rheumatoid arthritis (RA) is characterized by chronic pol-
yarthritis and primary inflammation of joint synovium, and
causes joint dysfunction because of destruction of bones
and joints [1]. Inflammatory cytokines, such as Tumor
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Necrosis Factor-a (TNF-a), Interleukin-1 (IL-1), and IL-6,
are produced in synoviocytes of RA, and these cytokines
play important roles in the onset and progression of RA [2–
5]. Tacrolimus (TAC) is an immunosuppressive macrolide
discovered as a metabolite of Streptomyces tsukubaensis, an
actinomycete, at the laboratory of Fujisawa Pharmaceutical
Co., Ltd. (currently, Astellas Pharma Inc.) in 1984. TAC
specifically blocks T-cell activation through inhibition of
calcineurin, a dephosphorylation enzyme, and shows
immunosuppressant effects including suppression of pro-
duction of inflammatory cytokines and production of anti-
bodies from B cells. Studies reported that TAC improved
arthritis symptoms [6–9], and inhibited maturation and
differentiation of osteoclasts [10] with these properties.
TAC was approved for the indication of ‘‘RA (only in a case
of inadequate response to conventional therapies)’’ in Apr
11, 2005 [10–14]. The subsequently conducted drug use-
results survey [15], long-term specific drug use-results
survey, and post-marketing clinical study [16] confirmed
the safety and efficacy of TAC. Studies reported the recent
use of add-on TAC to patients with RA with inadequate
responses to methotrexate (MTX) and patients with RA
who could not use a sufficient dose of MTX because of
adverse drug reactions (ADRs) and complications [17, 18].
Although reduction of clinical symptoms used to be the
therapeutic goal in the past, the emergence of biological
disease-modifying anti-rheumatic drugs (DMARDs) has
made remission an achievable goal in recent RA treatment.
On the other hand, biological DMARDs fail to achieve
adequate suppression of disease activity or the efficacy of
biological DMARDs is reduced in some patients. Dose
increase of biological DMARDs, switch to other biological
DMARDs, and add-on use or dose increase of conventional
anti-rheumatic drugs are therapeutic options for such
patients, and there are studies reporting the usage of add-on
TAC [19–23]. Infliximab and etanercept were the only
marketed biological DMARDs at the time of the drug use-
results survey and long-term specific drug use-results sur-
vey of TAC, and few patients were using TAC adding on to
these two drugs [15]. Therefore, the safety and efficacy of
TAC adding on to biological DMARDs have not been
sufficiently confirmed in the real clinical setting. A specific
drug use-results survey of TAC (clinicaltrials.gov identifier:
NCT01870908) was conducted to evaluate the safety and
effectiveness of add-on TAC in patients with RA who failed
to show an adequate response to biological DMARDs. We
report here the interim results of 172 patients analyzed for
safety and 165 patients analyzed for effectiveness among
175 patients who had completed the observation period and
had their data collected before October 2013.
2 Methods
2.1 Survey Patients
The survey was conducted in patients with RA who failed
to show an adequate response to biological DMARDs. An
inadequate response to biological DMARDs was defined if
all of the following conditions were met: a Simplified
Disease Activity Index (SDAI) [24] score of[3.3 when
TAC was started; both the tender joint count (TJC) and
swollen joint count (SJC) were the same or increased
compared with those at 4–8 weeks prior to the start of
TAC; and biological DMARDs were used for at least
8 weeks prior to the start of TAC.
2.2 Survey Methods
The survey employs a central registration method, and
patients who are administered TAC after the investigator
has signed off the survey agreement will be registered
within 14 days after the first dose of TAC. The observation
period was 24 weeks from the first day of administration of
TAC, the investigation period was 2 years and 8 months,
from August 2012 to March 2015, and the enrollment
period was 2 years and 2 months, from August 2012 to
September 2014. This survey was conducted in compliance
with the ordinance on ‘‘Good Post-Marketing Study Prac-
tice’’ (GPSP), which was authorized by the Ministry of
Health, Labour and Welfare in Japan (Ordinance No. 171,
dated 20 December 2004). Institutional review board
approval was obtained according to the rules of each
institution as required for a post marketing surveillance
(PMS) study, and a contract with all medical facilities
participating in this study was constructed. Written
informed consent was not obtained, as the PMS study in
Japan is allowed to be conducted without informed
consents.
2.3 Investigational Items and Timing
2.3.1 Patient Backgrounds
The investigational items are sex, age at the start of
administration, body weight, RA duration, presence/ab-
sence of complication and name of complication,
presence/absence of medical history and name of dis-
ease, Steinbrocker stage classification [25], Steinbrocker
functional classification [25], rheumatoid factor [26],
and anti-cyclic citrullinated peptide (anti-CCP) antibody
[27].
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2.3.2 Status of RA Therapy
For administration of TAC, the investigational items are
daily dose, duration of treatment, and reason for discon-
tinuation. For the status of RA therapy with other drugs, the
investigational items are the dose of and duration of
treatment with MTX, steroids, and biological DMARDs.
2.3.3 Safety Evaluation
The safety endpoints are presence/absence of adverse events
(AEs) (including ADRs, laboratory values, and other
abnormal laboratory values), AE term, date of onset, seri-
ousness, action taken to TAC, symptomatic therapy, event
outcome, date of outcome, causal relationship to TAC, and
factors other than TAC. ADRs were defined as AEs in which
the causal relationship to TAC was not ruled out by the
investigator, and were tabulated by the System Organ Class
(SOC) and Preferred Term (PT) using the Medical Dic-
tionary for Regulatory Activities/Japanese (MedDRA/J)
Version 16.1. SOCs are tabulated in the number of patients
with events, and PTs are tabulated in the number of events. If
events of the same PT occurred more than once in the same
patient, they were counted as one event for tabulation. The
following seven items were analyzed as key investigational
items: ‘‘infection,’’ ‘‘renal impairment,’’ ‘‘glucose tolerance
impaired,’’ ‘‘cardiac dysfunction,’’ ‘‘pancreatic dysfunc-
tion,’’ ‘‘psychoneurologic disorder,’’ and ‘‘lymphoma.’’
2.3.4 Effectiveness Evaluation
The effectiveness endpoints are SDAI, Disease Activity
Score 28–C-reactive protein (DAS28-CRP) [28, 29],
improvement as determined by the European League
Against Rheumatism (EULAR) criteria [30], modified
Health Assessment Questionnaire (mHAQ) scores [31],
and serum matrix metalloproteinase-3 (MMP-3) [32]
levels. Because data at 4–8 weeks prior to the start of TAC
were collected as historical data in this survey, observation
points were set to the following four time points:
4–8 weeks prior to the start of TAC, at the start of TAC,
12 weeks after the start of TAC (week 12), and 24 weeks
after the start of TAC (week 24). Each effectiveness end-
point was analyzed in patients who were evaluated at the
start of TAC and after the start of TAC (at week 12 or 24),
and data evaluated during treatment with TAC and during
treatment with biological DMARDs, which had been used
at the start of TAC, were used.
2.4 Statistical Methods
Continuous variables were presented as mean ± standard
deviation (SD), and nominal variables were presented as
the number of patients (%). All analyses were performed
using SAS (version 9.2) in this survey. In the effective-
ness evaluation, missing values after the start of TAC were
imputed using the last observation carried forward (LOCF)
method for distribution of SDAI disease activity, changes
in SDAI scores over time, distribution of DAS28-CRP
disease activity, changes in DAS28-CRP scores over time,
improvement as determined by EULAR criteria, changes in
TJC over time, changes in SJC over time, changes in
Visual Analog Scale (VAS) by physicians over time,
changes in VAS by patients over time, changes in C-re-
active protein (CRP) over time, changes in mHAQ scores
over time, and changes in serum MMP-3 levels over time.
The comparisons of the data at each observation point
versus the start of TAC were tested with Wilcoxon signed-
rank test. All p values presented were two-sided, and a
significance level of 5 % was used for each comparison.
3 Results
3.1 Disposition of Patients and Patient Backgrounds
The disposition of patients is shown in Fig. 1. Of the 175
patients collected, 172 patients (excluding patients out of
the scope of the survey and patients who did not come to
the survey site after the first dose) were analyzed for safety,
and 165 patients (excluding patients who were not evalu-
ated for effectiveness) were analyzed for effectiveness.
Fig. 1 Disposition of patients. One hundred seventy-five patients
were collected, 172 patients were analyzed for safety, and 165
patients were analyzed for effectiveness. 1One patient who was out of
the scope of the survey was also the patient who made no subsequent
hospital visits after the initial administration. 2One patient had an
SDAI of B3.3 when administration of TAC was started; one patient
had (TJC at 4–8 weeks prior to the start of TAC)[ (TJC at the start
of administration of TAC); one patient either had a missing value for
SDAI at the start of TAC or an unknown start date for administration
of biological DMARDs. DMARDs disease-modifying anti-rheumatic
drugs, SDAI Simplified Disease Activity Index, TAC tacrolimus, TJC
tender joint count
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The demographic characteristics of the 172 patients ana-
lyzed for safety are shown in Table 1. Of the patients, 151
(87.8 %) were female, and age (mean ± SD) was
61.9 ± 12.1 years, body weight (mean ± SD) 54.2 ±
10.0 kg, andRAduration (mean ± SD) 11.0 ± 8.3 years. A
total of 132 patients (76.7 %) had complications; the most
common complication was osteoporosis in 101 patients
(58.7 %), followed by hypertension in 26 patients (15.1 %).
A total of 41 patients (25.0 %) had a medical history; the
most common medical history was appendicitis in four
patients (2.4 %) and pneumonia in four patients (2.4 %),
followed by gastric ulcer in three patients (1.8 %). The
Steinbrocker stage classification was Stage III in 50 patients
(30.9 %) and Stage IV in 50 patients (30.9 %). The Stein-
brocker functional classification was Class 3 in 31 patients
(19.4 %) and Class 4 in one patient (0.6 %). The rheumatoid
factor was positive in 121 patients (80.1 %), and anti-CCP
antibody was positive in 70 patients (86.4 %).
3.2 Status of RA Therapy
The status of administration of TAC is shown in Fig. 2. In
the safety analysis set, the initial dose was
1.1 ± 0.5 mg/day, and the mean dose in the observation
period was 1.3 ± 0.6 mg/day. The highest proportion was
1.0 mg/day throughout the observation period, and the
dose was titrated up from the start of TAC
(1.1 ± 0.5 mg/day) to week 24 (1.4 ± 0.7 mg/day). In the
analysis by elderly (C65 years) and non-elderly
(\65 years) patients, the dose was titrated up from the
start of TAC (elderly 1.1 ± 0.5 mg/day; non-elderly
1.2 ± 0.5 mg/day) to week 24 (elderly 1.3 ± 0.6 mg/day;
non-elderly 1.5 ± 0.7 mg/day), and the mean daily dose
in elderly patients was lower than that in non-elderly
patients throughout the observation period (data not
shown). Administration of TAC was continued up to week
24 in 87.2 % of patients, and the disposition of reason for
discontinuation before week 24 was AEs in nine patients,
unchanged/worsening of symptoms in nine patients, and
request by patients in five patients. One patient out of
‘‘unchanged/worsening of symptoms’’ and one patient out
of ‘‘patient’s request’’ are the same patient.
The status of RA therapy is shown in Table 2. Patients
who had been treated with the first concomitant biological
DMARD at the start of TAC showed the highest propor-
tion, with 112 patients (65.1 %), followed by the second
concomitant biological DMARD in 36 patients (20.9 %).
Patients who had been using concomitant etanercept at the
start of TAC showed the highest proportion, with 41
patients (23.8 %), followed by infliximab in 34 patients
Table 1 Patient backgrounds
Item Number of patients (%)
Patients analyzed for safety 172 (–)
Sex (n = 172)
Male 21 (12.2)
Female 151 (87.8)







Mean ± SD 61.9 ± 12.1
Body weight (kg) (n = 154)
\40 4 (2.6)
C40 to\50 44 (28.6)
C50 to\60 69 (44.8)
C60 to\70 23 (14.9)
C70 14 (9.1)
Mean ± SD 54.2 ± 10.0
Disease duration (years) (n = 153)
\5 45 (29.4)
C5 to\10 43 (28.1)
C10 65 (42.5)
Mean ± SD 11.0 ± 8.3





Pneumonia interstitial 24 (14.0)





Gastric ulcer 3 (1.8)
Steinbrocker stage classification (n = 162)
Stage I 18 (11.1)
Stage II 44 (27.2)
Stage III 50 (30.9)
Stage IV 50 (30.9)
Steinbrocker functional classification (n = 160)
Class 1 19 (11.9)
Class 2 109 (68.1)
Class 3 31 (19.4)
Class 4 1 (0.6)
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(19.8 %). The mean time to the first biological DMARD
after onset of RA was 8.1 ± 7.6 years; ‘‘C5 years’’
accounted for approximately 50 %, and ‘‘C10 years’’
accounted for approximately 34.6 % (53 patients). The
mean duration of treatment with biological DMARDs,
which had been used at the start of TAC, before the start of
TAC was 1.8 ± 1.8 years, and C50 % of patients had been
using biological DMARDs for at least 1 year before TAC.
MTX was coadministered in 116 patients (67.4 %), and
steroids were coadministered in 95 patients (55.2 %).
There was no significant change in the MTX dose from the
start of TAC until week 24, and the mean MTX dose
remained at 8.0–8.2 mg/week. Similarly, there was no
significant change in the daily dose of oral steroids (pred-
nisolone equivalent) from the start of TAC until week 24,
and the mean daily dose remained at 4.1–4.4 mg/day.
3.3 Safety
3.3.1 Status of Development of ADRs
The status of development of ADRs in the 172 patients
analyzed for safety is shown in Table 3. A total of 22
ADRs occurred in 18 patients (10.5 %). ADRs that
occurred in at least two events were abdominal pain (two
events), stomatitis (two events), and malaise (two events).
Serious ADRs were herpes zoster (one event) and
myocardial infarction (one event). Herpes zoster occurred
at 19 days after the start of TAC, but administration of
TAC was continued and the event was later resolved by an
antiviral drug. The causal relationship to TAC was ‘‘un-
likely related.’’ The patient who experienced myocardial
infarction was 89 years old at the start of TAC, RA dura-
tion was 31 years, Steinbrocker stage classification was
Stage IV, and Steinbrocker functional classification was
Class 3. Myocardial infarction occurred at 103 days after
the start of TAC, and the patient died on the same day. The
causal relationship to TAC and factors other than TAC
were ‘‘unknown.’’
3.3.2 Key Investigational Items
‘‘Infection,’’ ‘‘renal impairment,’’ ‘‘cardiac dysfunction,’’
and ‘‘glucose tolerance impaired’’ occurred in four patients
(2.3 %), two patients (1.2 %), one patient (0.6 %), and one
patient (0.6 %), respectively. ‘‘Pancreatic dysfunction,’’
Table 1 continued
Item Number of patients (%)




Quantitative level unknown 8 (5.3)
Negative 30 (19.9)




Quantitative level unknown 12 (14.8)
Negative 11 (13.6)
Anti-CCP anti-cyclic citrullinated peptide, SD standard deviation
a Complications in 20 or more patients shown (multiple answers)
b Medical history in three or more patients shown (multiple answers)
Fig. 2 Status of administration
of TAC from the start of TAC to
week 24. The bar chart
indicates distribution of dose,
and the line chart indicates the
mean dose. SD standard
deviation, TAC tacrolimus
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‘‘psychoneurologic disorder,’’ and ‘‘lymphoma’’ did not
occur.
3.4 Effectiveness
The distribution of SDAI disease activity is shown in
Fig. 3. The proportion of remission (SDAI B3.3) or low
disease activity (3.3\ SDAI B 11) was 46.3 % at
4–8 weeks prior to the start of TAC, 0.0 % for remission
and 20.0 % for low disease activity at the start of TAC, 8.9
Table 2 Status of RA therapy
Item Number of patients (%)
Patients analyzed for safety 172 (–)
Concomitant MTX used 116 (67.4)
Concomitant steroids used 95 (55.2)















Time to first biological DMARDs after onset of RA (years) (n = 153)
\5 76 (49.7)
C5 to\10 24 (15.7)
C10 53 (34.6)
Mean ± SD 8.1 ± 7.6
Duration of treatment with biological DMARDs used before the start
of TAC (years) (n = 172)
\0.5 44 (25.6)
C0.5 to\1 38 (22.1)
C1 to\2 30 (17.4)
C2 to\3 19 (11.0)
C3 to\4 17 (9.9)
C4 to\5 15 (8.7)
C5 9 (5.2)
Mean ± SD 1.8 ± 1.8
DMARD disease-modifying anti-rheumatic drug, MTX methotrexate,
RA rheumatoid arthritis, SD standard deviation, TAC tacrolimus
a Including biological DMARDs being used at the start of TAC
Table 3 List of status of development of ADRs
Number (%)
Patients analyzed for safety 172
Number of patients with ADRs 18
Number of ADRs 22
Incidence of ADRs (10.5)
Type of ADRs (number of patients)
Infections and infestations 4 (2.3)
Cystitis escherichia 1 (0.6)
Herpes zoster 1 (0.6)
Pneumonia 1 (0.6)
Sinusitis 1 (0.6)
Metabolism and nutrition disorders 1 (0.6)
Glucose tolerance impaired 1 (0.6)
Cardiac disorders 1 (0.6)
Myocardial infarction 1 (0.6)
Gastrointestinal disorders 7 (4.1)
Abdominal pain 2 (1.2)
Stomatitis 2 (1.2)




Gastritis erosive 1 (0.6)
Skin and subcutaneous tissue disorders 1 (0.6)
Rash 1 (0.6)
Renal and urinary disorders 1 (0.6)
Renal impairment 1 (0.6)




Blood creatinine increased 1 (0.6)
White blood cell count decreased 1 (0.6)
Key investigational items (number of patients)
Infection 4 (2.3)
Cystitis escherichia 1 (0.6)
Herpes zoster 1 (0.6)
Pneumonia 1 (0.6)
Sinusitis 1 (0.6)
Renal impairment 2 (1.2)
Blood creatinine increased 1 (0.6)
Renal impairment 1 (0.6)
Cardiac dysfunction 1 (0.6)
Myocardial infarction 1 (0.6)
Glucose tolerance impaireda 1 (0.6)
Glucose tolerance impairedb 1 (0.6)
ADR adverse drug reaction
a System Organ Class (SOC) b Preferred Term (PT)
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and 40.7 %, respectively, at week 12, and 13.3 and 45.2 %,
respectively, at week 24, showing improvement. The mean
(±SD) SDAI score was 13.6 ± 8.3 at 4–8 weeks prior to
the start of TAC, 20.1 ± 10.3 at the start of TAC,
13.4 ± 9.4 at week 12, and 11.7 ± 9.1 at week 24; the
mean SDAI score reduced over time after the start of TAC
(Fig. 4). The distribution of DAS28-CRP disease activity is
shown in Fig. 5. The proportion of remission (DAS28-
CRP\2.3) or low disease activity (2.3 B DAS28-
CRP\ 2.7) was 33.6 % at 4–8 weeks prior to the start of
TAC, 3.7 % for remission and 6.7 % for low disease
activity at the start of TAC, 24.4 and 14.8 %, respectively,
at week 12, and 33.3 and 15.6 %, respectively, at week 24,
showing improvement. The mean (±SD) DAS28-CRP
score was 3.3 ± 1.1 at 4–8 weeks prior to the start of TAC,
4.0 ± 1.0 at the start of TAC, 3.2 ± 1.2 at week 12, and
2.9 ± 1.2 at week 24; the mean DAS28-CRP score reduced
over time after the start of TAC (Fig. 6). Improvement as
determined by EULAR criteria is shown in Fig. 7.
Moderate response or good response was achieved in
60.7 % at week 12 and in 69.8 % at week 24. Changes over
time in mean values (±SD) of TJC, SJC, VAS by physi-
cians, VAS by patients, and CRP levels were also evalu-
ated (Figs. 8, 9, 10, 11, 12). The TJC was 3.2 ± 3.8 at
Fig. 3 Distribution of SDAI disease activity from 4 to 8 weeks prior
to the start of TAC to week 24, using LOCF method. Disease activity
was defined using SDAI scores as follows: remission, SDAI B3.3;
low disease activity, 3.3\SDAI B 11; moderate disease activity,
11\SDAI B 26; high disease activity, 26\SDAI. LOCF last
observation carried forward, SDAI Simplified Disease Activity Index,
TAC tacrolimus
Fig. 4 Changes in SDAI scores (mean ± SD) from 4 to 8 weeks
prior to the start of TAC to week 24, using LOCF method.
Improvements were seen at week 12 (p\ 0.001) and at week 24
(p\ 0.001). LOCF last observation carried forward, SD standard
deviation, SDAI Simplified Disease Activity Index, TAC tacrolimus
Fig. 5 Distribution of DAS28-CRP disease activity from 4 to
8 weeks prior to the start of TAC to week 24, using LOCF method.
Disease activity was defined using DAS28-CRP scores as follows:
remission, DAS28-CRP\2.3; low disease activity, 2.3 B DAS28-
CRP B 2.7; moderate disease activity, 2.7 B DAS28-CRP B 4.1;
high disease activity, 4.1\DAS28-CRP. DAS28-CRP Disease Activ-
ity Score 28–C-reactive protein, LOCF last observation carried
forward, TAC tacrolimus
Fig. 6 Changes in DAS28-CRP scores (mean ± SD) from 4 to
8 weeks prior to the start of TAC to week 24, using LOCF method.
Improvements were seen at week 12 (p\ 0.001) and at week 24
(p\ 0.001). DAS28-CRP Disease Activity Score 28–C-reactive
protein, LOCF last observation carried forward, SD standard devia-
tion, TAC tacrolimus
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4–8 weeks prior to the start of TAC, 5.5 ± 4.9 at the start
of TAC, 3.1 ± 4.0 at week 12, and 2.7 ± 4.2 at week 24.
The SJC was 2.8 ± 3.3, 4.7 ± 4.3, 2.7 ± 3.7, and
2.3 ± 3.0, respectively. The VAS by physicians was
3.2 ± 2.1, 4.0 ± 2.0, 2.9 ± 2.1, and 2.6 ± 2.0, respec-
tively. The VAS by patients was 3.7 ± 2.4, 4.5 ± 2.5,
3.6 ± 2.6, and 3.3 ± 2.5, respectively. The CRP level was
1.1 ± 1.5, 1.4 ± 1.7, 0.8 ± 1.2, and 0.7 ± 1.0, respec-
tively. All of them reduced over time after the start of
TAC. The mean (±SD) mHAQ score, physical function
evaluation by patients, was 1.0 ± 0.6, 1.2 ± 0.5,
1.0 ± 0.6, and 1.0 ± 0.6, respectively, and reduced over
time after the start of TAC (Fig. 13). The mean (±SD)
serum MMP-3 level was 160.2 ± 220.8, 193.8 ± 248.8,
153.0 ± 206.3, and 154.0 ± 221.0, respectively, and the
values after the start of TAC were lower than those at the
start of TAC (Fig. 14).
4 Discussion
This survey started in August 2012 to evaluate the safety
and effectiveness of add-on TAC in patients with RA who
failed to show an adequate response to biological
DMARDs. This report is a summary of interim results of
the demographic characteristics, status of RA therapy, and
the safety and effectiveness in 172 patients analyzed for
safety and 165 patients analyzed for effectiveness. In the
patients analyzed for this survey, the mean age was
61.9 years and RA duration was 11.0 years, and patients
were relatively at an old age with long-term RA. The mean
daily dose of TAC was titrated up from the start of TAC
(1.1 mg/day) to week 24 (1.4 mg/day), and the mean daily
dose throughout the observation period was 1.3 mg. Other
studies of the add-on use of TAC to patients with RA who
Fig. 7 Improvement rate at week 12 and at week 24 determined by
EULAR criteria (DAS28-CRP), using LOCF method. DAS28-CRP
Disease Activity Score 28–C-reactive protein, EULAR European
League Against Rheumatism, LOCF last observation carried forward
Fig. 8 Changes in TJC (mean ± SD) from 4 to 8 weeks prior to the
start of TAC to week 24, using LOCF method. Significant reductions
were seen at week 12 (p\ 0.001) and at week 24 (p\ 0.001). LOCF
last observation carried forward, SD standard deviation, TAC
tacrolimus, TJC tender joint count
Fig. 9 Changes in SJC (mean ± SD) from 4 to 8 weeks prior to the
start of TAC to week 24, using LOCF method. Significant reductions
were seen at week 12 (p\ 0.001) and at week 24 (p\ 0.001). LOCF
last observation carried forward, SD standard deviation, SJC swollen
joint count, TAC tacrolimus
Fig. 10 Changes in VAS (mean ± SD) by physicians from 4 to
8 weeks prior to the start of TAC to week 24, using LOCF method.
Significant reductions were seen at week 12 (p\ 0.001) and at week
24 (p\ 0.001). LOCF last observation carried forward, SD standard
deviation, TAC tacrolimus, VAS Visual Analog Scale
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failed to show an adequate response to biological
DMARDs also reported the use of TAC at lower doses than
the approved dose [19–21], and our interim results were
similar to the results in these studies. Patients who had
been treated with the first biological DMARD at the start of
TAC showed the highest proportion at 65.1 %, and few
patients repeatedly switched biological DMARDs. In the
safety evaluation, the incidence of ADRs was 10.5 %.
ADRs that occurred in at least two events were abdominal
pain, stomatitis, and malaise (two events each). No ADR
showed a significantly high incidence, and all of these
ADRs could be expected from ‘‘Precautions for Use’’ in the
package insert. Serious ADRs were herpes zoster and
myocardial infarction (one event each). The outcome of
myocardial infarction was death, and the causal
relationship to TAC and factors other than TAC were
‘‘unknown.’’ The impact of predispositions of the patient
was considered to have had a major impact because this
was a patient with severe RA aged 89 years, who had a
long-time RA duration of 31 years, Steinbrocker stage
classification Stage IV, and Steinbrocker functional clas-
sification Class 3. The effectiveness was evaluated
according to the remission criteria of the SDAI announced
by the American College of Rheumatology and the
EULAR in 2010. Remission or low disease activity was
achieved in 49.6 % at week 12, and in 58.5 % at week 24.
We will continue to evaluate the safety and effectiveness in
large numbers of patients (e.g., tabulation by biological
DMARD) to delineate the clinical significance of TAC
Fig. 11 Changes in VAS (mean ± SD) by patients from 4 to
8 weeks prior to the start of TAC to week 24, using LOCF method.
Significant reductions were seen at week 12 (p\ 0.001) and at week
24 (p\ 0.001). LOCF last observation carried forward, SD standard
deviation, TAC tacrolimus, VAS Visual Analog Scale
Fig. 12 Changes in CRP (mean ± SD) from 4 to 8 weeks prior to the
start of TAC to week 24, using LOCF method. Significant reductions
in serum CRP levels were seen at week 12 (p\ 0.001) and at week 24
(p\ 0.001). CRP C-reactive protein, LOCF last observation carried
forward, SD standard deviation, TAC tacrolimus
Fig. 13 Changes in mHAQ scores (mean ± SD) from 4 to 8 weeks
prior to the start of TAC to week 24, using LOCF method.
Improvements in mHAQ responses were seen at week 12
(p = 0.003) and at week 24 (p\ 0.001). LOCF last observation
carried forward, mHAQ modified Health Assessment Questionnaire,
SD standard deviation, TAC tacrolimus
Fig. 14 Changes in serum MMP-3 levels (mean ± SD) from 4 to
8 weeks prior to the start of TAC to week 24, using LOCF method.
Significant reductions in serum MMP-3 levels were seen at week 12
(p\ 0.001) and at week 24 (p\ 0.001). LOCF last observation
carried forward, MMP-3 matrix metalloproteinase-3, SD standard
deviation, TAC tacrolimus
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adding on to biological DMARDs in patients who failed to
achieve an adequate response to biological DMARDs, and
ensure to provide information on appropriate use.
Acknowledgments These survey results were originally published
in the Journal of New Remedies and Clinics (a Japanese journal), and
have been reproduced here with the permission of the publisher,
Iyaku-Joho-Kenkyujo, Inc. We would like to thank the many physi-
cians who cooperated and provided us with valuable data for this
survey.
Compliance with Ethical Standards
This study was sponsored by Astellas Pharma Inc., Tokyo, Japan. KI,
KS and TY are employees of Astellas Pharma Inc.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation
in rheumatoid arthritis. N Engl J Med. 2001;344(12):907–16.
2. Breedveld FC, Dayer JM. Leflunomide: mode of action in the
treatment of rheumatoid arthritis. Ann RheumDis. 2000;59:841–9.
3. Weyand CM. New insights into the pathogenesis of rheumatoid
arthritis. Rheumatology. 2000;39(Suppl. 1):3–8.
4. Arend WP, Dayer JM. Inhibition of the production and effects of
interleukin-1 and tumor necrosis factor alpha in rheumatoid
arthritis. Arthritis Rheum. 1995;38:151–60.
5. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima
T, et al. FK-506, a novel immunosuppressant isolated from a
Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.
J Antibiot (Tokyo). 1987;40:1256–65.
6. Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu
T, et al. Effect of a new immunosuppressive agent, FK 506, on
heterotopic cardiac allotransplantation in the rat. Transplant Proc.
1987;19(1 Pt 2):1284–6.
7. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata
S, et al. FK506 potently inhibits T cell activation induced TNF-a
and IL-1b production in vitro by human peripheral blood
mononuclear cells. Br J Pharmacol. 2000;130:1655–63.
8. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y,
et al. Effects of FK506 and other immunosuppressive anti-rheu-
matic agents on T cell activation mediated IL-6 and IgM pro-
duction in vitro. Int Immunopharmacol. 2001;1:749–57.
9. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Com-
parison of anti-arthritic properties of leflunomide with
methotrexate and FK506: effect on T cell activation-induced
inflammatory cytokine production in vitro and rat adjuvant
induced arthritis. Inflamm Res. 2004;53:544–50.
10. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H.
Contribution of nuclear factor of activated T cells c1 to the
transcriptional control of immunoreceptor osteoclast-associated
receptor but not triggering receptor expressed by myeloid cells-2
during osteoclastogenesis. J Biol Chem. 2005;280(38):32905–13.
11. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M,
et al. Efficacy and safety of TAC (FK506) in treatment of
rheumatoid arthritis: a randomized, double-blind, placebo-con-
trolled dose-finding study. J Rheumatol. 2004;31:243–51.
12. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT,
Borton MA, et al. Efficacy and safety of tacrolimus in patients
with rheumatoid arthritis: a double-blind trial. Arthritis Rheum.
2003;48:3328–37.
13. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Sch-
nitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis
patients who have been treated unsuccessfully with methotrexate
: a six-month, double-blind, randomized, dose-ranging study.
Arthritis Rheum. 2002;46:2020–8.
14. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T.
Comparison of tacrolimus and mizoribine in a randomized,
double-blind controlled study in patients with rheumatoid
arthritis. J Rheumatol. 2006;33:2153–61.
15. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K,
Miyasaka N. Post-marketing surveillance of the safety and
effectiveness of tacrolimus in 3,267 Japanese patients with
rheumatoid arthritis. Mod Rheumatol. 2014;24(1):8–16.
16. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N.
Efficacy and safety of additional use of tacrolimus in patients
with early rheumatoid arthritis with inadequate response to
DMARDs–a multicenter, double-blind, parallel-group trial. Mod
Rheumatol. 2011;21(5):458–68.
17. Kitahama M, Nakajima A, Inoue E, Taniguchi A, Momohara S,
Yamanaka H. Efficacy of adjunct tacrolimus treatment in patients
with rheumatoid arthritis with inadequate responses to
methotrexate. Mod Rheumatol. 2013;23(4):788–93.
18. Kanzaki T, Kawahata K, Kanda H, Fujio K, Kubo K, Akahira L,
et al. Long-term therapeutic effects and safety of tacrolimus
added to methotrexate in patients with rheumatoid arthritis.
Rheumatol Int. 2013;33(4):871–7.
19. Naniwa T, Watanabe M, Banno S, Maeda T. Adding low dose
tacrolimus in rheumatoid arthritis patients with an inadequate
response to tumor necrosis factor inhibitor therapies. Rheumatol
Int. 2009;29(11):1287–91.
20. Mori S. Additional use of tacrolimus after switching to tocilizu-
mab therapy in patients with primary lack of efficacy of inflix-
imab therapy for rheumatoid arthritis. Mod Rheumatol. 2012;
22(6):947–50.
21. Miyata M, Asano T, Satoh S. Effect of additional administration
of tacrolimus in patients with rheumatoid arthritis treated with
biologics. Fukushima J Med Sci. 2011;57(2):54–9.
22. Fujibayashi T, Takahashi N, Kida D, Kaneko A, Hirano Y,
Fukaya N, et al. Comparison of efficacy and safety of tacrolimus
and methotrexate in combination with abatacept in patients with
rheumatoid arthritis; a retrospective observational study in the
TBC Registry. Mod Rheumatol. 2015. doi:10.3109/14397595.
2015.1029238.
23. Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D,
et al. Concomitant methotrexate and tacrolimus augment the
clinical response to abatacept in patients with rheumatoid arthritis
with a prior history of biological DMARD use. Rheumatol Int.
2015. doi:10.1007/s00296-015-3283-4.
24. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits
J, et al. American College of Rheumatology/European League
Against Rheumatism provisional definition of remission in
rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;
63(3):573–86.
25. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria
in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62.
26. van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA, van
Soesbergen RM, Fiselier TJ, et al. Radiologic features in juvenile
idiopathic arthritis: a first step in the development of a stan-
dardized assessment method. Arthritis Rheum. 2003;48(2):
507–15.
316 K. Ishida et al.
27. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of
biomarkers in juvenile idiopathic arthritis patients and their sig-
nificant association with disease severity: a comparative study.
Clin Exp Rheumatol. 2008;26(3):492–7.
28. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al.
Disease Activity Score 28 (DAS28) using C-reactive protein
underestimates disease activity and overestimates EULAR
response criteria compared with DAS28 using erythrocyte sedi-
mentation rate in a large observational cohort of rheumatoid
arthritis patients in Japan. Ann Rheum Dis. 2007;66(9):1221–6.
29. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Com-
parison of Disease Activity Score (DAS)28-erythrocyte sedi-
mentation rate and DAS28- C-reactive protein threshold values.
Ann Rheum Dis. 2007;66(3):407–9.
30. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J,
et al. 3.Validation of the 28-joint Disease Activity Score (DAS28)
and European League Against Rheumatism response criteria
based on C-reactive protein against disease progression in
patients with rheumatoid arthritis, and comparison with the
DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis.
2009;68(6):954–60.
31. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP.
Assessment of patient satisfaction in activities of daily living
using a modified Stanford Health Assessment Questionnaire.
Arthritis Rheum. 1983;26(11):1346–53.
32. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H,
Taniguchi A, et al. Serum matrix metalloproteinase 3 as a pre-
dictor of the degree of joint destruction during the six months
after measurement, in patients with early rheumatoid arthritis.
Arthritis Rheum. 2000;43(4):852–8.
Add-On Tacrolimus in RA Patients with Inadequate Response to Biological DMARDs 317
